Reshaping the HIV treatment and prevention landscape
mRNA: an important technology in our pipeline
Our differentiated mRNA approach to enable
multivalent and combination vaccines
5' and 3' optimisation (CureVac)
VNTS
Investing at pace and building capabilities
-
mRNA research centre in Rockville (USA)
->200 GSK mRNA scientists globally
Virus Neutralising Titers (VNTs) by dose (n=6;4(buffer), day 21)
-
2560
1280
640
360
160
80
40
UREVAC
0000
00000
00000
00000
20
10
5
Buffer
0,5 μg
1st Gen platform
2 μg
8 μg
2nd Gen platform
20 μα
40 μα
(do) d21
d42
- 10x higher immune response allowing for lower doses*
-
Refrigerator-stable (2-8°C)
Further optimisation using modified bases
*preclinical data in animal models
6 clinical candidates in the next 4 years
- 2 assets in clinic within 12 months
- COVID-19 booster; multi-valent, addressing
emerging variants
- Improved seasonal influenza with multi-antigen
construct
- Combination (COVID/Flu) under evaluation
gsk
61View entire presentation